<DOC>
	<DOCNO>NCT02169505</DOCNO>
	<brief_summary>The goal clinical research study study safety ADCETRISTM ( brentuximab vedotin ) patient Hodgkin lymphoma ALCL allogeneic haploidentical stem cell transplant . Another goal study learn brentuximab vedotin help prevent disease come back .</brief_summary>
	<brief_title>Brentuximab Vedotin High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation ( AlloSCT )</brief_title>
	<detailed_description>Study Drug Administration : If agree take part study , 35-60 day transplant , receive brentuximab vedotin vein 30 minute Day 1 21-day study cycle . You may receive 6 cycle brentuximab vedotin . At Cycles 3 beyond , receive high dose study drug receive Cycles 1 2 . Study Visits : About 5 day Day 1 Cycle 1 : - You physical exam . As part physical exam , check graft-versus-host disease ( GVHD -- transplant donor tissue attack tissue recipient 's body ) . You may additional blood draw check GVHD part standard care . - Blood ( 2 tablespoon ) draw routine test check transplant take . - Blood ( 2 teaspoon time ) drawn dose study drug check immune system . On Days 3 5 Cycle 1 , blood ( 2 teaspoon ) draw check immune system . About 5 day Day 1 Cycles 2-6 : - You physical exam . - Blood ( 2 tablespoon ) draw routine test check immune system . If doctor think need , may skin biopsy endoscopy check GVHD and/or graft failure . You sign separate consent form explain procedure risk . Length Study : You take study 1 year transplant . You longer able take study drug disease get bad , intolerable side effect occur , develop infection ( cytomegalovirus [ CMV ] respond treatment ) , unable follow study direction . Your participation study follow-up visit . Follow-Up Visits : About 1 , 3 , 6 , 12 month transplant , follow-up visit part standard care transplant . At visit : - You physical exam - Blood ( 4 tablespoon ) draw routine test , learn transplant take , check status disease . - You compute tomography ( CT ) scan check status disease . - You bone marrow biopsy aspiration check status disease cytogenetic testing . To collect bone marrow biopsy/aspirate , area hip site numb anesthetic , small amount bone marrow bone withdrawn large needle . Cytogenetic test look genetic change cell may affect disease may react study drug . This investigational study . Brentuximab vedotin FDA approve commercially available treatment Hodgkin lymphoma ALCL . It investigational give brentuximab vedotin early time transplant . Up 20 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients CD30 positive Hodgkin Lymphoma ( HL ) anaplastic large cell lymphoma ( ALCL ) undergone allogeneic haploidentical SCT past 60 day ( match relate matched unrelated donor ) . 2 . Age 18 65 year . 3 . Performance status : Zubrod 01 Karnofsky 80100 . 4 . Serum creatinine &lt; 1.5 mg/dL creatinine clearance great equal 40 cc/min define MDRD method National Kidney Disease Education Program ( NKDEP ) . 5 . Serum direct bilirubin &lt; 1.5 mg/dL ( unless Gilbert 's syndrome ) . 6 . SGPT &lt; 200 IU/L unless related patient 's malignancy . 7 . Evidence neutrophil platelet engraftment , define platelet count equal great 50,000 mm3 independent platelet transfusion ANC equal great 1000 without growth factor support least 5 day . 8 . Patients previous exposure brentuximab pretransplant eligible study . 1 . Pregnancy breastfeeding ( woman childbearing potential , female experience menarche undergone surgical sterilization postmenopausal positive serum pregnancy test . 2 . Presence steroidrefractory acute graftversushost disease ( GVHD ) . 3 . Patients underwent allogeneic transplantation treatment graft failure . 4 . Dual refractory CMV reactivation foscarnet ganciclovir evidence CMV disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>HL</keyword>
	<keyword>CD30 positive Hodgkin Lymphoma</keyword>
	<keyword>Anaplastic large cell lymphoma</keyword>
	<keyword>ALCL</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>ASCT</keyword>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Brentuximab Vedotin</keyword>
	<keyword>SGN-35</keyword>
	<keyword>Adcetris</keyword>
</DOC>